Financing will be used to advance Rewind's lead oral program designed to promote remyelination and restore neurological function

融资将用于推进Rewind的领先口服药物项目，该项目旨在促进髓鞘再生并恢复神经功能

Peer-reviewed data published in PLOS ONE demonstrated remyelination and functional recovery following oral treatment with a selective GPR17 antagonist in preclinical models

发表在《PLOS ONE》上的同行评审数据显示，在临床前模型中，口服选择性GPR17拮抗剂治疗后，出现了髓鞘再生和功能恢复。

LEUVEN, Belgium, Oct. 06, 2026 (GLOBE NEWSWIRE) --

比利时鲁汶，2026年10月6日（环球电讯社）--

Rewind Therapeutics ('Rewind'),

Rewind Therapeutics（“Rewind”），

a biotechnology company developing small-molecule therapies to restore myelin in demyelinating diseases, today announced that it has secured additional financing to advance the development of its lead GPR17 antagonist program, a potential disease modifying oral therapy intended to promote remyelination and restore neurological function in multiple sclerosis (MS)..

一家致力于开发小分子疗法以修复脱髓鞘疾病中髓鞘的生物技术公司，今日宣布已获得额外融资，以推进其领先的GPR17拮抗剂项目的研发。该项目是一种潜在的疾病修饰性口服疗法，旨在促进多发性硬化症（MS）患者的髓鞘再生并恢复神经功能。

MS is a chronic neurological disease characterized by damage to myelin, the protective coating surrounding nerve fibers. While currently available therapies can help control inflammatory disease activity, there are no approved therapies specifically designed to restore lost myelin and repair damaged nerves..

多发性硬化症（MS）是一种慢性神经系统疾病，其特征是包裹神经纤维的保护性涂层——髓鞘受损。虽然目前可用的疗法有助于控制炎症性疾病活动，但尚无专门用于恢复丢失的髓鞘和修复受损神经的获批疗法。

The financing marks an important milestone for Rewind as it advances its lead GPR17 antagonist program toward the clinic. The company plans to complete key IND-enabling studies while building on a growing body of preclinical and translational evidence supporting GPR17 as a potential therapeutic target for remyelination..

此次融资标志着Rewind在其领先的GPR17拮抗剂项目向临床应用推进的过程中迈出了重要里程碑。公司计划在不断积累的、支持GPR17作为潜在髓鞘再生治疗靶点的临床前和转化证据基础上，完成关键的IND申报所需研究。

Jim Van heusden, Executive Chair of Rewind Therapeutics, said:

Rewind Therapeutics 执行主席 Jim Van Heusden 表示：

“Having secured additional funding, we are well positioned to advance our GPR17 program towards its next value-inflection point. The recent data support both the biology and therapeutic potential of GPR17 antagonism and strengthen our confidence as we advance the program towards clinical development.”.

“在获得额外资金后，我们已具备有利条件，推动GPR17项目迈向下一个价值拐点。近期数据不仅支持GPR17拮抗作用的生物学基础和治疗潜力，也增强了我们在推进该项目进入临床开发阶段的信心。”

In July 2026, Rewind scientists and collaborators at the Netherlands Institute for Neuroscience and Amsterdam UMC, published '

2026年7月，Rewind的科学家及其在荷兰神经科学研究所和阿姆斯特丹大学医学中心的合作者发表了

Selective GPR17 antagonism enhances structural and functional recovery in animal models of demyelination

选择性GPR17拮抗作用增强脱髓鞘动物模型的结构和功能恢复

' in PLOS ONE. The data showed that once-daily oral treatment with a selective GPR17 antagonist accelerated remyelination and improved functional outcomes in acute and chronic models of demyelination.

发表于《PLOS ONE》。数据显示，选择性GPR17拮抗剂的每日一次口服治疗可加速脱髓鞘急性和慢性模型中的髓鞘再生，并改善功能结局。

Irene Knuesel, PhD, Chief Scientific Officer of Rewind Therapeutics, commented:

Rewind Therapeutics 首席科学官 Irene Knuesel 博士评论道：

“While many approaches can demonstrate new myelin formation, the critical question is whether this translates into functional recovery. Our data show that oral GPR17 antagonism improves both nerve conduction along the visual pathway and cognitive performance, supported by human MS tissue findings that reinforce the underlying biology.

“尽管许多方法能够证明新髓鞘的形成，但关键问题在于这是否转化为功能恢复。我们的数据显示，口服GPR17拮抗剂可改善沿视觉通路的神经传导以及认知表现，而来自人类多发性硬化症组织的研究结果进一步支持了这一潜在生物学机制。”

As we advance our lead program through IND-enabling studies, emerging preclinical evidence also points to a broader role for GPR17 in metabolic regulation, including obesity.”.

随着我们通过新药临床试验申请（IND） enabling 研究推进我们的领先项目，新兴的临床前证据也表明 GPR17 在代谢调节（包括肥胖）中发挥着更广泛的作用。

Post-mortem analysis of tissue from people with multiple sclerosis showed that GPR17-expressing oligodendrocyte precursor cells accumulate within and around demyelinated lesions, whereas remyelinated lesions exhibited little or no GPR17. These findings support the role of GPR17 as a key negative regulator of myelin repair.

对多发性硬化症患者组织的尸检分析显示，表达GPR17的少突胶质前体细胞在脱髓鞘病变内部及周围积聚，而再髓鞘化病变中GPR17的表达极少或没有。这些发现支持GPR17作为髓鞘修复关键负调控因子的作用。

In acute and chronic cuprizone models, once-daily oral treatment with a selective Rewind GPR17 antagonist accelerated remyelination of the corpus callosum and optic nerve. Importantly, treatment also resulted in functional recovery, including normalization of visual evoked potential (VEP) latency delays and improved spatial memory performance..

在急性和慢性杯佐酮模型中，每日一次口服选择性Rewind GPR17拮抗剂可加速胼胝体和视神经的髓鞘再生。重要的是，治疗还带来了功能恢复，包括视觉诱发电位（VEP）潜伏期延迟的恢复正常以及空间记忆表现的改善。

Rewind’s management team will be available for meetings at:

Rewind 的管理团队将在以下时间接受会议预约：

Optimum Strategic Communications’ 18th Annual Healthcare Investor Conference

Optimum Strategic Communications 第十八届年度医疗保健投资者大会

, October 8, 2026, London, UK

2026年10月8日，英国伦敦

BIO-Europe 2026

2026年欧洲生物大会

, November 9–11, 2026, Cologne, Germany

2026年11月9日至11日，德国科隆

Jefferies Global Healthcare Conference

杰富瑞全球医疗保健会议

, November 16–19, 2026, London, UK

2026年11月16日至19日，英国伦敦

To request a meeting, please contact

如需安排会议，请联系

information@rwdtx.com

information@rwdtx.com

or

或

rewind@optimumcomms.com

rewind@optimumcomms.com

.

。

Reference: De Herdt D, Lefevere E, Brouwers V, et al. (2026). Selective GPR17 antagonism enhances structural and functional recovery in animal models of demyelination. PLOS ONE 21(7): e0354525.

参考文献：De Herdt D, Lefevere E, Brouwers V, 等 (2026). 选择性GPR17拮抗作用增强脱髓鞘动物模型的结构和功能恢复. PLOS ONE 21(7): e0354525.

https://doi.org/10.1371/journal.pone.0354525

https://doi.org/10.1371/journal.pone.0354525

For more information, please contact:

如需更多信息，请联系：

Rewind Therapeutics

Rewind Therapeutics

Jim Van heusden, Executive Chair

吉姆·范赫斯登，执行主席

Email:

电子邮件：

information@rwdtx.com

information@rwdtx.com

Optimum Strategic Communications

最佳战略传播

Zoe Bolt, Nellie Stephens & Katherine Bliss

佐伊·博尔特、内莉·斯蒂芬斯和凯瑟琳·布利斯

Tel: +44 (0) 20 3882 9621

电话：+44 (0) 20 3882 9621

Email:

电子邮件：

rewind@optimumcomms.com

rewind@optimumcomms.com

About Rewind Therapeutics

关于 Rewind Therapeutics

Rewind Therapeutics develops oral small-molecule therapeutics aimed at re-initiating remyelination in patients with debilitating neurological diseases such as multiple sclerosis and optic neuritis. These diseases share a common feature: loss of the myelin sheath, the protective layer that insulates nerve fibres.

Rewind Therapeutics 致力于开发口服小分子疗法，旨在重新启动多发性硬化症和视神经炎等致残性神经系统疾病患者的髓鞘再生过程。这些疾病具有一个共同特征：即作为神经纤维绝缘保护层的髓鞘丧失。

Rewind's lead programme targets GPR17, a key regulator of oligodendrocyte maturation, with the goal of restoring the central nervous system's intrinsic capacity to repair myelin. Rewind's team combines extensive R&D expertise with a strong patent estate in remyelination therapeutics. Headquartered in Leuven, Belgium, Rewind is backed by leading life-science investors, including Boehringer Ingelheim Venture Fund, M Ventures, PMV, Golgi Neurosciences, Sunstone Life Science Ventures, Gemma Frisius Fonds and CD3, KU Leuven.

Rewind 的核心研发项目靶向 GPR17（少突胶质细胞成熟的关键调节因子），旨在恢复中枢神经系统内在的髓鞘修复能力。Rewind 团队将深厚的研发专长与在髓鞘再生疗法领域的强大专利组合相结合。公司总部位于比利时鲁汶，并获得包括勃林格殷格翰风险投资基金、M Ventures、PMV、Golgi Neurosciences、Sunstone Life Science Ventures、Gemma Frisius Fonds 以及 CD3（鲁汶大学）在内的领先生命科学投资机构的支持。

For further information, please visit: https://rwdtx.com/.

如需更多信息，请访问：https://rwdtx.com/。